RWP
TEVA icon

RWA Wealth Partners’s Teva Pharmaceuticals TEVA Stock Holding History

RWA Wealth Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,118
Closed -$27K – 646
2018
Q2 		$27K Buy
1,118
+518
+86% +$10.6K ﹤0.01% 501
2018
Q1 		$10K Buy
+600
New +$11.7K ﹤0.01% 452

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

RWA Wealth Partners's TEVA Position: Q3 2018 in Review

RWA Wealth Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2018, closing a stake of 1,118 shares — an estimated $27K sold.

RWA Wealth Partners first reported a position in TEVA in Q1 2018 and held it in 2 quarters. The position peaked at $27K in Q2 2018. 557 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

  • RWA Wealth Partners reported no remaining Teva Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • RWA Wealth Partners sold 1,118 Teva Pharmaceuticals shares in Q3 2018, an estimated $27K.
  • RWA Wealth Partners first reported a position in Teva Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • RWA Wealth Partners's Teva Pharmaceuticals position peaked at $27K in Q2 2018.
  • 557 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on RWA Wealth Partners's 13F filing for Q3 2018, filed 14 Nov 2018.